Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration

Nov.06.2024
Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Tom Beaudet, CEO of U.S. compliance firm Accorto, reviewed the effectiveness of past bipartisan policies and predicts that the FDA will improve its review process, allowing e-cigarette products to gain market approval more quickly in the future.

The results of the 2024 U.S. presidential election have been revealed, with Donald Trump elected as the new president. As the largest e-cigarette market in the world, the direction and regulatory policies of the U.S. market have significant global implications. How the new administration will regulate e-cigarettes and the future of the U.S. e-cigarette market are questions drawing global industry attention. As a leading global vaping technology media and think tank, 2Firsts quickly connected with U.S. compliance experts to provide the most authoritative analysis.

 

Tom Beaudet, CEO of U.S. compliance firm Accorto, shared with 2Firsts his thoughts on the regulatory approaches and actions of both the Trump administration and the current Democratic government on e-cigarettes. He emphasized that, during the current administration's four years, only 9 harm-reduction product applications were approved, despite millions of applications being submitted. He predicts that under the next administration, the FDA may gradually establish a clearer market entry pathway, helping companies that submit complete scientific data gain market access more quickly.

 

Trump wins U.S. election | Expert analysis on e-cigarette policy direction under the next administration
Accorto CEO Tom Beaudet | Image source: 2Firsts

 

Read the full perspective from Tom Beaudet:

 

  • Several weeks ago, ex President Donald Trump made the statement that he saved flavored vapes in 2020 and that, if he is elected again, he will save flavors again. However, it must be remembered that flavored closed pod systems were banned during the Trump presidency.

 

  • During the past 4 years, FDA has only approved 9 new harm reduction products, although applications have been submitted for millions of new products.  Although the vast majority of those applications were not complete with the scientific data needed for substantive review by the CTP Office of Science, several companies did submit high quality applications and are still awaiting a final decision.  Many question why we should expect anything different under another Democratic Party administration.

 

  • There is hope, regardless of who walks away victorious on November 5.  The US VTA, led by their president Tony Abud, has been aggressively working to educate members of Congress from both parties about the life saving potential of Nicotine Harm Reduction products and the importance of making changes at FDA to repair the currently broken review process.  Regardless of who wins tomorrow, we should expect to see improvements in the PMTA review process where applications who spend the money and time to submit high quality applications have a known and proven pathway to a Market Granted Order.  As more products are approved and we develop a pool of predicate products to reference, the known pathway to success will be come more and more established.

 


 

2Firsts will continue to bring the latest reports and interpretations on U.S. e-cigarette policies.

 

Disclaimer: This article represents only the views of the expert.

Oregon Senate Passes Bill to Regulate Nicotine Pouches as Tobacco Products
Oregon Senate Passes Bill to Regulate Nicotine Pouches as Tobacco Products
The Oregon Senate voted 26–1 to pass Senate Bill 1571, a measure redefining tobacco products to include nicotine pouches and restricting their sale to individuals under 21.
Regulations
Feb.23
Uzbekistan to impose full ban on nicotine delivery devices from March 1,2026
Uzbekistan to impose full ban on nicotine delivery devices from March 1,2026
Uzbekistan will enforce a total ban on the circulation of electronic nicotine delivery systems from March 1, covering legal sales, storage and imports. Consumers are offered a legal option to avoid criminal liability by voluntarily handing prohibited devices to law enforcement. The report says imports had already effectively stalled in early 2025, leaving sellers to clear remaining stock.
Feb.27 by 2FIRSTS.ai
Russia dismantles illegal vape liquid plant near Moscow; goods worth about $13 million seized
Russia dismantles illegal vape liquid plant near Moscow; goods worth about $13 million seized
Russian authorities say they have dismantled an illegal vape-liquid production site in the Moscow region, seizing four production lines, large quantities of components and finished goods, and substantial cash. The Interior Ministry estimated the seized products’ value at about 1 billion rubles (≈$13 million) and said the operation ran around the clock, producing up to 75,000 units per shift.
Feb.10 by 2FIRSTS.ai
Australia’s NSW Finds Lower Vaping Rates Among Teenagers Aged 14 to 17
Australia’s NSW Finds Lower Vaping Rates Among Teenagers Aged 14 to 17
A new report from Cancer Council’s Generation Vape research project shows that fewer teenagers in New South Wales are trying vaping after the state government introduced tougher vaping goods laws. Among surveyed NSW teenagers aged 14 to 17, the proportion who had tried vaping fell from 29.6% in April 2024 to 20.1% in October 2025.
Mar.17 by 2FIRSTS.ai
Bangladesh May Remove E-Cigarette Production and Sales Ban in Tobacco Law Amendment
Bangladesh May Remove E-Cigarette Production and Sales Ban in Tobacco Law Amendment
Bangladesh is preparing amendments to its anti-tobacco ordinance that would remove the ban on the production and sale of e-cigarettes and also delete provisions prohibiting the display of tobacco products at points of sale.
Mar.31 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11